| # | Title | Journal | Year | Citations |
|---|
| 1 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia | New England Journal of Medicine | 2001 | 4,825 |
| 2 | Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells | Nature Medicine | 1996 | 3,357 |
| 3 | Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome | New England Journal of Medicine | 2001 | 2,593 |
| 4 | Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B | Nature Medicine | 2012 | 682 |
| 5 | Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy | Blood | 2007 | 563 |
| 6 | OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML | New England Journal of Medicine | 2013 | 499 |
| 7 | Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Annals of Oncology | 2013 | 481 |
| 8 | The ploidy conveyor of mature hepatocytes as a source of genetic variation | Nature | 2010 | 432 |
| 9 | Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval | JAMA Internal Medicine | 2017 | 333 |
| 10 | The high price of anticancer drugs: origins, implications, barriers, solutions | Nature Reviews Clinical Oncology | 2017 | 289 |
| 11 | Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival | JAMA Internal Medicine | 2015 | 287 |
| 12 | Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells | Blood | 2000 | 282 |
| 13 | Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome | Nature Genetics | 2001 | 278 |
| 14 | The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM | Nature Genetics | 2000 | 252 |
| 15 | Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. | Journal of Biological Chemistry | 1994 | 244 |
| 16 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia | Leukemia | 2013 | 230 |
| 17 | The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells | Cancer Discovery | 2019 | 215 |
| 18 | Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia | Journal of Biological Chemistry | 1994 | 203 |
| 19 | Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies | Journal of Thrombosis and Haemostasis | 2017 | 191 |
| 20 | Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism | Nature Genetics | 1999 | 190 |
| 21 | STI571: Targeting BCR‐ABL as Therapy for CML | Oncologist | 2001 | 190 |
| 22 | The SH3 Domain-binding T Cell Tyrosyl Phosphoprotein p120 | Journal of Biological Chemistry | 1995 | 178 |
| 23 | Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers | Nature Reviews Clinical Oncology | 2018 | 177 |
| 24 | STI571: A Paradigm of New Agents for Cancer Therapeutics | Journal of Clinical Oncology | 2002 | 176 |
| 25 | Common Mutation in Methylenetetrahydrofolate Reductase | Circulation | 1996 | 164 |
| 26 | The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment | Blood | 2013 | 162 |
| 27 | p120 Is a Major Substrate of Tyrosine Phosphorylation upon B Cell Antigen Receptor Stimulation and Interacts in Vivo with Fyn and Syk Tyrosine Kinases, Grb2 and Shc Adaptors, and the p85 Subunit of Phosphatidylinositol 3-Kinase | Journal of Biological Chemistry | 1996 | 161 |
| 28 | Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future | Cancer | 2016 | 158 |
| 29 | Cbl-mediated Negative Regulation of the Syk Tyrosine Kinase | Journal of Biological Chemistry | 1998 | 156 |
| 30 | CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins | Blood | 1997 | 156 |
| 31 | Stimulation through the T Cell Receptor Induces Cbl Association with Crk Proteins and the Guanine Nucleotide Exchange Protein C3G | Journal of Biological Chemistry | 1996 | 153 |
| 32 | Involvement of SH2-containing Phosphotyrosine Phosphatase Syp in Erythropoietin Receptor Signal Transduction Pathways | Journal of Biological Chemistry | 1995 | 139 |
| 33 | Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571 | Journal of Biological Chemistry | 2002 | 139 |
| 34 | Protein tyrosine kinases and cancer | Biochimica Et Biophysica Acta: Reviews on Cancer | 1997 | 138 |
| 35 | Transplanted human bone marrow contributes to vascular endothelium | Proceedings of the National Academy of Sciences of the United States of America | 2004 | 131 |
| 36 | Calcitriol in cancer treatment: From the lab to the clinic | Molecular Cancer Therapeutics | 2004 | 125 |
| 37 | Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons | Journal of Biological Chemistry | 1999 | 120 |
| 38 | The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation | EMBO Journal | 2001 | 120 |
| 39 | Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites | Oncogene | 2002 | 117 |
| 40 | A Phase I trial of pulse calcitriol in patients with refractory malignancies | Cancer | 2001 | 116 |
| 41 | Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review | ASAIO Journal | 2021 | 115 |
| 42 | CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells | Journal of Biological Chemistry | 1995 | 114 |
| 43 | The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients | European Journal of Haematology | 2020 | 112 |
| 44 | Testosterone Loss and Estradiol Administration Modify Memory in Men | Journal of Urology | 2006 | 110 |
| 45 | Association Between Physician Orders for Life‐Sustaining Treatment for Scope of Treatment and In‐Hospital Death in Oregon | Journal of the American Geriatrics Society | 2014 | 108 |
| 46 | A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel | Cancer | 2008 | 106 |
| 47 | Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma | Cancer | 2016 | 106 |
| 48 | A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia | Science Translational Medicine | 2014 | 105 |
| 49 | Patient‐physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer | Cancer | 2008 | 102 |
| 50 | Calcitriol in cancer treatment: from the lab to the clinic | Molecular Cancer Therapeutics | 2004 | 100 |
